Last updated: September 22, 2023
Sponsor: Seqirus
Overall Status: Active - Recruiting
Phase
3
Condition
Vaccines
Influenza
Treatment
N/AClinical Study ID
TX318205
V201_03
Ages 50-99 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Individuals ≥50 years of age on the day of informed consent
- Healthy individuals or individuals with stable comorbidities which increase their risk of complications from influenza infection.
Exclusion
Exclusion Criteria:
- Progressive, unstable, or uncontrolled clinical conditions.
- Hypersensitivity, including allergy, to any component of vaccines whose use is foreseen in this study.
- Known history of Guillain-Barré syndrome or another demyelinating disease such as encephalomyelitis and transverse myelitis.
Study Design
Study Start date:
Estimated Completion Date:
Study Description
Connect with a study center
AMR Kansas City (formerly Center for Pharmaceutical Research)
Kansas City, Missouri 64114
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.